BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 12452875)

  • 1. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial.
    Peris K; Campione E; Micantonio T; Marulli GC; Fargnoli MC; Chimenti S
    Dermatol Surg; 2005 Mar; 31(3):318-23. PubMed ID: 15841634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
    Vidal D; Alomar A
    Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
    Geisse JK; Rich P; Pandya A; Gross K; Andres K; Ginkel A; Owens M
    J Am Acad Dermatol; 2002 Sep; 47(3):390-8. PubMed ID: 12196749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
    Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
    J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imiquimod: in superficial basal cell carcinoma.
    Oldfield V; Keating GM; Perry CM
    Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
    Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
    Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cutaneous tumors with topical 5% imiquimod cream.
    Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
    Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
    Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
    Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
    Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.
    van der Geer S; Martens J; van Roij J; Brand E; Ostertag JU; Verhaegh ME; Neumann HA; Krekels GA
    Br J Dermatol; 2012 Jul; 167(1):110-5. PubMed ID: 22385074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
    Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
    Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
    Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
    J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
    Ozolins M; Williams HC; Armstrong SJ; Bath-Hextall FJ
    Trials; 2010 Apr; 11():42. PubMed ID: 20409337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.